<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cutaneous adverse effects of conventional chemotherapy agents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cutaneous adverse effects of conventional chemotherapy agents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cutaneous adverse effects of conventional chemotherapy agents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cuong V Nguyen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lida Zheng, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Systemic and local treatments for cancer can cause a number of changes in the skin, mucous membranes, hair, and nails [<a href="#rid1">1-6</a>]. When dermatologic lesions arise in patients being treated for cancer, they may represent an adverse effect of therapy, but other etiologies need to be considered. These include a cutaneous reaction to other drugs, exacerbation of a previously existing condition, infection, metastatic tumor involvement, a paraneoplastic phenomenon, graft-versus-host disease, or a nutritional disorder.</p><p>The accurate diagnosis and management of chemotherapy-related side effects requires the clinician to be knowledgeable about the most common cutaneous reaction patterns for the drugs the patient is receiving. The clinician must also be familiar with the cutaneous manifestations of certain cancers, as well as the dermatologic effects of other forms of cancer treatments. In some cases, diagnostic uncertainty can only be clarified with a rechallenge, and the clinician must determine whether a rechallenge with a lower dose, if appropriate, is safe and medically justifiable.</p><p>The cutaneous adverse effects of conventional cytotoxic cancer therapy agents are presented here. Other mucocutaneous complications of cancer treatment are discussed separately. Infusion reactions are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2088.html" rel="external">"Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/103060.html" rel="external">"Hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15764.html" rel="external">"Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2797.html" rel="external">"Extravasation injury from cytotoxic and other noncytotoxic vesicants in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1156.html" rel="external">"Alopecia related to systemic cancer therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1152.html" rel="external">"Oral toxicity associated with systemic anticancer therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/128565.html" rel="external">"Cutaneous immune-related adverse events associated with immune checkpoint inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2835.html" rel="external">"Infusion reactions to systemic chemotherapy"</a>.)</p><p></p><p class="headingAnchor" id="H375590834"><span class="h1">TOXIC ERYTHEMA OF CHEMOTHERAPY</span><span class="headingEndMark"> — </span>The term "toxic erythema of chemotherapy" refers to a group of cutaneous reactions induced by conventional chemotherapy agents (most frequently <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a>, fluoropyrimidines [<a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>], <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>) with overlapping clinical and histopathologic features [<a href="#rid7">7</a>]. The most frequently seen clinical presentation involves the hands and feet and is known as "hand-foot syndrome"  (<a class="graphic graphic_picture graphicRef79857" href="/d/graphic/79857.html" rel="external">picture 1</a>). Other terms that have been used include acral erythema, palmar-plantar erythrodysesthesia, toxic acral erythema, and Burgdorf's reaction. </p><p>The pathogenesis, clinical presentation, diagnosis, treatment, and prevention of toxic erythema of chemotherapy are discussed separately. (See  <a class="medical medical_review" href="/d/html/142102.html" rel="external">"Toxic erythema of chemotherapy (hand-foot syndrome)"</a>.)</p><p class="headingAnchor" id="H2954899912"><span class="h1">NEUTROPHILIC ECCRINE HIDRADENITIS</span><span class="headingEndMark"> — </span>Neutrophilic eccrine hidradenitis (NEH) is a reactive, self-limited disorder that may occur in association with malignancy (with or without chemotherapy), infections, and certain medications [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/5571.html" rel="external">"Neutrophilic dermatoses", section on 'Neutrophilic eccrine hidradenitis'</a>.)</p><p>The original description of drug-induced NEH was in a patient receiving <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> for acute myeloid leukemia [<a href="#rid9">9</a>]. Since then, a variety of chemotherapeutic agents have been associated with this entity that may be considered within the spectrum of toxic erythema of chemotherapy  (<a class="graphic graphic_table graphicRef50193" href="/d/graphic/50193.html" rel="external">table 1</a>) [<a href="#rid1">1,10,11</a>]. However, the cause of NEH in patients receiving chemotherapy remains elusive. It is postulated that a high concentration of the drug in sweat has a direct toxic effect on the eccrine glands [<a href="#rid12">12,13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Patients present with the eruption one to two weeks after therapy with the offending agent. The clinical presentation is nonspecific. Lesions are typically asymptomatic, erythematous, edematous plaques but may be purpuric and painful. They can be located on the extremities  (<a class="graphic graphic_picture graphicRef99020" href="/d/graphic/99020.html" rel="external">picture 2A</a>), trunk, and face  (<a class="graphic graphic_picture graphicRef99027" href="/d/graphic/99027.html" rel="external">picture 2B</a>), including the periorbital region, where severe lesions may mimic cellulitis. Generalized, erythema multiforme-like lesions have been reported [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– Because the clinical picture is nonspecific, a biopsy should be performed in cases of suspected NEH to confirm the diagnosis. Histopathologic examination shows neutrophils surrounding the eccrine glands, vacuolar degeneration in glands and ducts, along with necrosis of lining cells, and squamous syringometaplasia of eccrine ducts  (<a class="graphic graphic_picture graphicRef139733" href="/d/graphic/139733.html" rel="external">picture 3</a>) [<a href="#rid12">12</a>]. Epidermal keratinocyte atypia is a common associated finding [<a href="#rid15">15</a>]. If chemotherapy-induced neutropenia is present, neutrophils may be absent on histologic examination. However, other characteristic findings, such as eccrine gland necrosis, are still identifiable [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The natural history is that of spontaneous resolution in one to two weeks [<a href="#rid16">16</a>]. While the reaction is self-limited and resolves without therapy, some studies support the use of systemic corticosteroids [<a href="#rid17">17</a>]. However, efficacy has not been established in randomized trials [<a href="#rid17">17</a>]. One case report suggests that oral <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> may be useful for prophylaxis [<a href="#rid18">18</a>]. The majority of patients with NEH will develop the same eruption with rechallenge.</p><p></p><p class="headingAnchor" id="H14"><span class="h1">PHOTOSENSITIVITY REACTIONS</span><span class="headingEndMark"> — </span>An increased sensitivity to ultraviolet (UV) light exposure (photosensitivity) has been associated with a variety of chemotherapy agents [<a href="#rid1">1,19-22</a>]. Photosensitivity reactions can be manifested in a variety of ways, including phototoxic reaction, photoallergic reaction, photorecall, and photoenhancement.</p><p class="headingAnchor" id="H15"><span class="h2">Phototoxic reactions</span><span class="headingEndMark"> — </span>A phototoxic reaction is a nonimmunologically mediated reaction that resembles an exaggerated sunburn, with erythema, edema, pain, and tenderness in sun-exposed areas, such as the face, the "V" area of the upper chest, and the dorsa of the hands. In severe cases, blistering can occur. Severe erythema develops within minutes to hours following light exposure. Postinflammatory hyperpigmentation is common.</p><p>The most common chemotherapeutic agent associated with phototoxic reactions is <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, although other antineoplastic agents, such as <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> and related compounds, <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>, and <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, may also be associated [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Phototoxicity'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– The pathogenesis of phototoxic chemotherapy reactions is thought to involve concentration of the drug within the skin and subsequent absorption of UV light, resulting in apoptosis of keratinocytes. Characteristic histologic findings include dyskeratotic keratinocytes, a vacuolar interface dermatitis, and papillary dermal edema with minimal inflammation [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical diagnosis</strong> – The clinical diagnosis is based upon the distribution of the eruption (ie, a sharp demarcation between sun-exposed versus protected sites)  (<a class="graphic graphic_picture graphicRef86479 graphicRef90426" href="/d/graphic/86479.html" rel="external">picture 4A-B</a>) and the temporal relationship to the administration of the offending agent. If the diagnosis is in doubt, photo patch testing can be used as adjunctive diagnostic measures [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The treatment of phototoxic reactions involves the discontinuation of the offending agent and avoidance of direct exposure to sunlight by using protective clothing and a topical sunscreen for at least two weeks. Physical sunscreens containing titanium oxide or <a class="drug drug_general" data-topicid="10326" href="/d/drug information/10326.html" rel="external">zinc oxide</a> are preferred because chemical sunscreens, especially oxybenzone, can be associated with photoallergic reactions (see  <a class="medical medical_review" href="/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a>). Symptomatic treatment with cool compresses and topical steroids may be helpful. Severe cases may require systemic steroids.</p><p></p><p>Patients receiving photosensitizing drugs should be counseled regarding the risk of adverse reactions to sunlight and encouraged to use UV protection with sunscreens and protective clothing.</p><p class="headingAnchor" id="H16"><span class="h2">Photoallergic reactions</span><span class="headingEndMark"> — </span>Photoallergic reactions are type IV, delayed hypersensitivity reactions that develop at least 24 hours after light exposure. In contrast to phototoxic reactions, a photoallergic reaction is characterized by a pruritic, papulovesicular eruption that involves sun-exposed areas but may spread to non-sun-exposed areas. Photosensitivity reactions to <a class="drug drug_general" data-topicid="8471" href="/d/drug information/8471.html" rel="external">flutamide</a> (an antiandrogen) and ftorafur (also called tegafur, a prodrug of <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>) are typically photoallergic rather than phototoxic [<a href="#rid19">19,25,26</a>]. Symptoms generally clear within four to eight weeks after drug discontinuation. (See  <a class="medical medical_review" href="/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Photoallergy'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Photorecall and photoenhancement</span><span class="headingEndMark"> — </span>A photorecall phenomenon (also called "UV reactivation reaction" or "solar burn reactivation reaction") occurs when the administration of a chemotherapy drug (typically <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> but also taxanes) triggers a sunburn-like reaction in the absence of light exposure in the same distribution as a sunburn that the patient may have sustained months to years before [<a href="#rid27">27-31</a>]. Symptoms are usually reproduced with rechallenge.</p><p>In contrast, photoenhancement occurs when patients who receive a drug (typically high-dose <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>) within two to five days of exposure to UV light develop severe erythema within the sun-exposed areas. In contrast to photoreactivation, retreatment with methotrexate does not usually reproduce this reaction. (See  <a class="medical medical_review" href="/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate"</a>.)</p><p>There are isolated reports of a photoenhancement phenomenon with taxanes, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a>, and some combination cytotoxic regimens [<a href="#rid28">28,32-35</a>].</p><p class="headingAnchor" id="H1547961498"><span class="h2">Inflammation of actinic keratoses</span><span class="headingEndMark"> — </span>There are isolated reports of patients receiving systemic chemotherapy, particularly cytotoxic chemotherapies, who developed erythematous papules and plaques in photodamaged areas that, on closer inspection, were actually inflamed actinic keratoses [<a href="#rid36">36-39</a>].</p><p class="headingAnchor" id="H21"><span class="h1">RADIATION RECALL DERMATITIS AND RADIATION ENHANCEMENT</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation recall dermatitis</strong> – Radiation recall dermatitis (RRD) is an uncommon, inflammatory skin reaction that develops in an area of previously irradiated skin after administration of certain promoting agents [<a href="#rid40">40</a>]. Most cases have been associated with chemotherapy. There may be a long interval between the administration of the causative agent and the appearance of RRD. The frequency of these reactions is unclear. In one study, RRD occurred in 8 of 91 patients (9 percent) who received chemotherapy following radiation therapy [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/13668.html" rel="external">"Radiation dermatitis", section on 'Radiation recall reaction'</a>.)</p><p></p><p class="bulletIndent1">RRD was originally described with <a class="drug drug_general" data-topicid="9318" href="/d/drug information/9318.html" rel="external">dactinomycin</a> [<a href="#rid42">42</a>]. Since then, a number of other drugs have also been associated with this phenomenon  (<a class="graphic graphic_table graphicRef77210" href="/d/graphic/77210.html" rel="external">table 2</a>), particularly anthracyclines and anthracycline-like drugs [<a href="#rid43">43-47</a>].</p><p></p><p class="bulletIndent1">The pathogenesis of RRD is controversial. An idiosyncratic hypersensitivity reaction has been proposed, with the "trauma" of prior radiation therapy sensitizing an area of skin into manifesting an immune reaction when there is little or no systemic activation (akin to the Koebner phenomenon) [<a href="#rid46">46</a>]. However, the occurrence of many of these reactions after the first drug exposure argues against an immune mechanism, and defects in deoxyribonucleic acid (DNA) repair [<a href="#rid48">48</a>] as well as toxic drug effects [<a href="#rid46">46</a>] have also been proposed as causative factors.</p><p></p><p class="bulletIndent1">Erythema, which may be painful, is the most common sign [<a href="#rid49">49,50</a>]. Vesiculation, desquamation, and ulceration have also been reported [<a href="#rid1">1</a>]. Histologically, epidermal dysplasia; necrotic keratinocytes; and a mixed, inflammatory reaction [<a href="#rid51">51</a>] characterize involved areas, with some cases showing psoriasiform dermatitis. Additional dermal changes include fibrosis, vasodilatation, and atypical fibroblasts. Many of these findings mimic the histologic findings of acute, severe sunburn or radiation dermatitis.</p><p></p><p class="bulletIndent1">RRD typically occurs with the first dose of the chemotherapy agent or combination and may require a minimum threshold radiation dose. In two case reports, patients receiving various doses of radiotherapy with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> or <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> had a radiation recall reaction only in those skin sites that had received the highest radiation dose [<a href="#rid52">52,53</a>]. Chemotherapy agents administered by the intravenous route usually produce RRD more rapidly (range, several minutes to 14 days) than oral agents, which have a longer lag period (range, three days to two months) [<a href="#rid54">54,55</a>].</p><p></p><p class="bulletIndent1">Drug interruption or dose reduction are the primary treatments for RRD. Symptomatic treatment includes topical corticosteroids and oral antihistamines. Rechallenge with the same agent does not always lead to symptom recurrence [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation enhancement</strong> – Enhancement of the cutaneous toxicity of radiation therapy can occur if a radiosensitizing chemotherapy drug is administered concurrently or within one week of radiation therapy [<a href="#rid1">1</a>]. The drugs that have been associated with radiation enhancement (also called radiation sensitizers) are listed in the table  (<a class="graphic graphic_table graphicRef77210" href="/d/graphic/77210.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1">Radiation enhancement involving the skin resembles RRD, with painful erythema, edema, superficial desquamation, and, if severe, erosions (wet desquamation). Similar to RRD, the eruption usually localizes to the irradiated field, but there may be local extension to unirradiated areas. Histologically, epidermal dysplasia; necrotic keratinocytes; and a mixed, inflammatory reaction characterize involved areas, with some cases showing psoriasiform dermatitis [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/13668.html" rel="external">"Radiation dermatitis"</a>.)</p><p></p><p class="bulletIndent1">Susceptibility to this effect decreases as the time between administration of chemotherapy and radiation therapy lengthens. In one report, superficial desquamation occurred in 50 percent of patients with lung cancer who received <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> within five days of radiation therapy, while no desquamative reactions occurred when the interval between radiation and chemotherapy was increased to three weeks [<a href="#rid57">57,58</a>].</p><p></p><p class="bulletIndent1">Possible explanations for the radiation-sensitizing effect of some chemotherapy drugs include increased blood supply and cellular reoxygenation to the tissue, interference with repair of radiation damage, competition for repair enzymes, and an increased percentage of cells in sensitive phases of the cell cycle [<a href="#rid59">59</a>]. For example, <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> arrests cell division in the G2 and M phases of the cell cycle, when cells are the most susceptible to ionizing radiation injury [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1">The eruption is usually self-limiting, resolving over a period of days to months. Treatment of radiation enhancement reactions is symptomatic and includes the application of cold compresses; local wound care to prevent infection; and the avoidance of trauma, irritation, heat, and ultraviolet (UV) light. Long-term sequelae may include skin atrophy, fibrosis, and telangiectasias. (See  <a class="medical medical_review" href="/d/html/7055.html" rel="external">"Clinical manifestations, prevention, and treatment of radiation-induced fibrosis"</a>.)</p><p></p><p class="bulletIndent1">The synergistic interaction between chemotherapy and radiation is exploited clinically in situations in which concurrent chemotherapy and radiation are administered to enhance antitumor effect (eg, concomitant fluoropyrimidines and radiation therapy for many gastrointestinal tumors). Since the target of the radiation beam is typically located deep within the body, enhanced skin toxicity is usually not a significant problem. Skin toxicity is seen more commonly with more superficial radiation fields. (See  <a class="medical medical_review" href="/d/html/2478.html" rel="external">"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus"</a>.)</p><p></p><p class="headingAnchor" id="H772366495"><span class="h1">PIGMENTARY CHANGES</span><span class="headingEndMark"> — </span>Pigmentary changes involving the skin, nails, and mucous membranes are common in patients receiving cytotoxic drugs, particularly alkylating agents and antitumor antibiotics  (<a class="graphic graphic_table graphicRef60304" href="/d/graphic/60304.html" rel="external">table 3</a>) [<a href="#rid61">61</a>]. The area of enhanced pigmentation may be localized or diffuse, and it may affect the skin, mucous membranes, hair, and/or nails. The pigmentary changes usually resolve with drug discontinuation but may persist. As an example, the rare, gingival margin hyperpigmentation seen with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> is usually permanent.</p><p class="headingAnchor" id="H268446166"><span class="h2">Diffuse hyperpigmentation</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">Fluorouracil</a> is one of the most ubiquitous drugs used in the treatment of malignancy. It is often associated with a hyperpigmentation reaction that may affect the skin diffusely, locally (in sun-exposed areas), or in a serpentine manner (a pigmentary pattern that follows an underlying vein proximal to an infusion site); darken the nail beds; and induce mucosal pigmentation of the tongue and conjunctiva. Topical fluorouracil can induce hyperpigmentation in treated areas. The fluorouracil derivative tegafur can induce well-circumscribed, brown to black, macular pigmentation that appears on the palms, soles, nails, and glans penis. The localization in these cases is unexplained. Hyperpigmentation associated with fluorouracil usually resolves within weeks to several months after cessation of therapy; however, in certain cases, nail hyperpigmentation may persist for years [<a href="#rid62">62-66</a>].</p><p>In addition to <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, many systemic medications induce pigmentary reaction patterns that affect the skin in a diffuse manner:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">Busulfan</a> causes a generalized skin darkening (the so-called "busulfan tan") that can mimic the cutaneous manifestations of Addison's disease. Although busulfan can also cause adrenal insufficiency, the skin pigmentary change is instead thought to be secondary to a toxic effect on melanocytes [<a href="#rid67">67,68</a>]. Features that can help to distinguish cutaneous busulfan toxicity from true Addison's disease include normal levels of melanocyte-stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH). (See  <a class="medical medical_review" href="/d/html/159.html" rel="external">"Clinical manifestations of adrenal insufficiency in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">Pegylated liposomal doxorubicin</a> can induce a macular hyperpigmentation over the trunk and extremities, including the palms and soles [<a href="#rid69">69</a>]. This reaction has not been described with unencapsulated <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> may induce hyperpigmentation of the face, neck, lower arms, palms, and nails; pigmentation can also be accentuated in areas of pressure or trauma [<a href="#rid70">70,71</a>]. This pressure-induced hyperpigmentation is also reported for <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> can rarely induce a diffuse, brown skin hyperpigmentation [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9815" href="/d/drug information/9815.html" rel="external">Procarbazine</a> has been associated with generalized melanosis [<a href="#rid74">74</a>].</p><p></p><p class="headingAnchor" id="H3225614842"><span class="h2">Localized hyperpigmentation</span><span class="headingEndMark"> — </span>Localized changes in skin pigmentation may be associated with intrinsic, anatomic features of the skin (eg, mucous membranes, skin creases, flexural or intertriginous areas, palms or soles, and the face). However, a suspected local drug reaction may be due to other extrinsic factors that act in combination with the drug. In addition to topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, other drugs that can induce localized hyperpigmentation include <a class="drug drug_general" data-topicid="9992" href="/d/drug information/9992.html" rel="external">thiotepa</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> (sites of adhesive placement on the skin); <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>, and <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> (sites of trauma or pressure); and <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a> (sun-exposed areas) [<a href="#rid1">1,75</a>]. The hyperpigmentation seen in areas of skin exposed to adhesive may reflect secretion of the drug in sweat.</p><p>Some of these reactions may represent postinflammatory hyperpigmentation rather than a local effect of the drug itself, especially if administration of the agent is associated with trauma, skin irritation, or a local allergic reaction (ie, contact dermatitis).</p><p>The following are examples of localized, chemotherapy-induced hyperpigmentation:</p><p class="bulletIndent1"><span class="glyph">●</span>The pigmentary changes caused by <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>, and <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> have a predilection for flexural areas and palmar creases. <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">Ifosfamide</a> hyperpigmentation can occur in flexural areas, the dorsal and plantar surfaces of the feet, the extensor surfaces of the fingers and toes, on the scrotum, and occasionally on large areas of the trunk. It may also occur under occlusive dressings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">Mitoxantrone</a> hyperpigmentation can affect the face, dorsum of the hands, and nails.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">Daunorubicin</a> may induce annular or polycyclic pigmentation of the scalp [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mucosal hyperpigmentation has been associated with <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (gingiva), tegafur (lower lip as well as glans penis), <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> (tongue and buccal mucosa), <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid1">1</a>], and <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Like topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="91010" href="/d/drug information/91010.html" rel="external">topical mechlorethamine</a> can induce hyperpigmentation in treated areas.</p><p></p><p class="headingAnchor" id="H665290881"><span class="h2">Patterned hyperpigmentation (serpentine, flagellate, reticular)</span><span class="headingEndMark"> — </span>Serpentine hyperpigmentation describes a supravenous, pigmentary pattern that follows the course of an underlying vein proximal to an infusion site. This phenomenon is most commonly seen with <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> but has also been associated with fotemustine, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>, and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> [<a href="#rid4">4</a>].</p><p>Serpentine hyperpigmentation has also been reported with some combination regimens, such as CHOP (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) for lymphoma treatment [<a href="#rid76">76,77</a>].</p><p>Linear (flagellate) hyperpigmentation  (<a class="graphic graphic_picture graphicRef112661" href="/d/graphic/112661.html" rel="external">picture 5</a>) may be seen with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> [<a href="#rid78">78,79</a>]. Multiple linear, erythematous or hyperpigmented streaks arise at sites of scratching or other minor traumas to the skin. Generalized pruritus is common and may precede the eruption.</p><p><a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">Paclitaxel</a>, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, and <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a> may induce a reticular hyperpigmentation predominantly located on the trunk and lower extremities [<a href="#rid80">80,81</a>]. Pruritus is often an accompanying symptom.</p><p class="headingAnchor" id="H476570997"><span class="h2">Hair color changes</span><span class="headingEndMark"> — </span>In addition to causing alopecia, chemotherapy can also cause pigmentary changes in hair (see  <a class="medical medical_review" href="/d/html/1156.html" rel="external">"Alopecia related to systemic cancer therapy"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Both <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> can induce hair color change. With cyclophosphamide, the range is from light red to black.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> may induce hyperpigmentation of scalp hair, eyebrow hair, and eyelashes. This tends to occur in bands that alternate with the normal color, a feature known as the "flag sign" [<a href="#rid82">82</a>]. This results from alternating periods of treatment and no treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One male patient receiving therapy with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> experienced hair color change from black to red [<a href="#rid1">1</a>].</p><p></p><p class="headingAnchor" id="H2113241406"><span class="h1">NAIL TOXICITIES</span></p><p class="headingAnchor" id="H3623324427"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Nonspecific nail changes are commonly observed during systemic cancer treatment [<a href="#rid83">83</a>]. They include transverse grooves on the nail plate (Beau lines) and onychomadesis (shedding of the nail) due to prolonged inactivation of the nail matrix  (<a class="graphic graphic_picture graphicRef62607 graphicRef78502" href="/d/graphic/62607.html" rel="external">picture 6A-B</a>). Fingernails grow approximately 0.1 mm per day. Thus, the distance of a Beau line from the proximal nail fold gives an approximate indication of when the acute insult occurred. (See  <a class="medical medical_review" href="/d/html/13682.html" rel="external">"Overview of nail disorders", section on 'Transverse grooves (Beau lines)'</a>.)</p><p>Cytotoxic chemotherapeutic agents have also been associated with pigmentary changes (chromonychia) and onycholysis, a detachment of the nail plate from the nail bed. Other inflammatory reaction patterns involving the nail folds include pyogenic granuloma and acute exudative paronychia that may progress to subungual abscess.</p><p>The various nail disorders that are associated with individual chemotherapy agents are summarized in the table  (<a class="graphic graphic_table graphicRef72242" href="/d/graphic/72242.html" rel="external">table 4</a>), and some are described below. After discontinuation of chemotherapy, all of these conditions generally resolve as the nail grows out.</p><p class="headingAnchor" id="H1075703308"><span class="h2">Melanonychia</span><span class="headingEndMark"> — </span>Medications may induce diffuse hyperpigmentation or banding/streaking of the nail plate (melanonychia striata) or bed. (See  <a class="medical medical_review" href="/d/html/121519.html" rel="external">"Longitudinal melanonychia"</a>.)</p><p>Besides <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, a wide range of agents have been implicated, including alkylating agents, taxanes, antimetabolites (<a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>), anthracyclines, and other antitumor antibiotics such as <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>  (<a class="graphic graphic_table graphicRef72242" href="/d/graphic/72242.html" rel="external">table 4</a>) [<a href="#rid1">1,83</a>]. Melanonychia appears one to two months after the initiation of chemotherapy and may be associated with cutaneous and mucosal hyperpigmentations. Taxanes may also induce a red nail discoloration, due to subungual hemorrhages, and true leukonychia  (<a class="graphic graphic_picture graphicRef85709" href="/d/graphic/85709.html" rel="external">picture 7</a>) [<a href="#rid84">84</a>]. Leukonychia is also observed in patients treated with <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, cyclophosphamide, or <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H4269558440"><span class="h2">Onycholysis</span><span class="headingEndMark"> — </span>Onycholysis is caused by inflammation in the nail bed, which leads to detachment of the overlying nail. The cytotoxic drugs most frequently associated with onycholysis are the taxanes <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>  (<a class="graphic graphic_picture graphicRef63373" href="/d/graphic/63373.html" rel="external">picture 8</a>) [<a href="#rid4">4</a>]. Other medications that have been reported to cause onycholysis include <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, <a class="drug drug_general" data-topicid="8909" href="/d/drug information/8909.html" rel="external">ixabepilone</a>, and the combination of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> plus <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a> [<a href="#rid1">1,86</a>].</p><p>An intriguing association between denervation and protection from chemotherapy-induced nail changes was suggested in a report of a patient with a complete right arm nerve palsy due to advanced breast cancer who developed docetaxel-related nail changes in all extremities except the paretic hand [<a href="#rid87">87</a>].</p><p>A systematic review of 12 studies supports the prophylactic use of frozen gloves and frozen socks for the prevention of taxane-induced nail and skin toxic effects [<a href="#rid88">88</a>]. However, the included studies were generally small and showed considerable methodologic heterogeneity regarding the cooling protocols, chemotherapy regimens, and choice of control limbs. Discomfort from cold may be reduced without changes in efficacy by using frozen gloves prepared at a temperature of -10 to -20°C (14 to -4°F) rather than at the standard temperature of -25 to -30°C (-13 to -22°F) [<a href="#rid89">89</a>].</p><p>A drawback of cold therapy may be a reduced exposure of the extremity to the therapeutic agent, which in theory may permit persistence of metastatic tumor cells in that location. Thus, the use of cold therapy to mitigate skin and nail toxicity must be decided on a case-by-case basis.</p><p class="headingAnchor" id="H4030355666"><span class="h2">Inflammatory changes</span><span class="headingEndMark"> — </span>A number of infectious and noninfectious, inflammatory changes of the nail folds and nail bed have been reported:</p><p class="bulletIndent1"><span class="glyph">●</span>Painful paronychial inflammation, often associated with pyogenic granulomas, may be induced by <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, and <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>. (See  <a class="medical medical_review" href="/d/html/5574.html" rel="external">"Paronychia"</a> and  <a class="medical medical_review" href="/d/html/13736.html" rel="external">"Pyogenic granuloma (lobular capillary hemangioma)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment with <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> and <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> may induce an exudative paronychia with or without progression to frank abscess [<a href="#rid4">4</a>].</p><p></p><p class="headingAnchor" id="H30"><span class="h1">EXANTHEMATOUS (MACULOPAPULAR) ERUPTIONS</span><span class="headingEndMark"> — </span>A wide variety of chemotherapy drugs have been associated with a mild, nonspecific, exanthematous drug eruption, including <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>, <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a>, and <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>. Lesions may be "morbilliform" or may consist of a profuse eruption of small, erythematous papules showing no resemblance to any infective exanthem. Morbilliform eruptions  (<a class="graphic graphic_picture graphicRef54205 graphicRef70062" href="/d/graphic/54205.html" rel="external">picture 9A-B</a>) are characterized by monomorphic, erythematous papules and are usually defined as "drug rash" in United States prescribing information and literature references.</p><p>The similarity of these rashes to those described for many other drugs underscores the importance of evaluating all medications taken by the patient before concluding that the rash is caused by the chemotherapy agent. (See  <a class="medical medical_review" href="/d/html/15762.html" rel="external">"Exanthematous (maculopapular) drug eruption"</a>.)</p><p>The management of patients with a presumptive chemotherapy drug rash is dictated by the severity of the reaction as well as the clinical circumstances surrounding the use of the individual chemotherapy agent. Pertinent issues include whether the offending agent is being used with curative versus palliative intent and whether a therapeutically equivalent substitute from another drug class is available. In mild cases, treatment with topical steroids is usually recommended, without specific modification of the chemotherapy regimen.</p><p>Pretreatment with corticosteroids is not usually recommended to prevent or diminish a chemotherapy-induced drug rash. One exception to this general rule is the drug <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a>, a folate analog used in the treatment of mesothelioma and non-small cell lung cancer. In an early phase 2 study, pemetrexed was associated with a papular skin rash in 66 percent of treated patients [<a href="#rid90">90</a>].</p><p>Subsequent phase 1, 2, and 3 trials reported a much lower incidence (less than 20 percent) and severity of skin rash, which was attributed to the routine use of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 4 mg twice daily for three days starting the day before treatment [<a href="#rid91">91-94</a>]. As a result, premedication with this schedule of dexamethasone has become a standard practice for patients receiving <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> [<a href="#rid92">92</a>]. Whether fewer doses would suffice is unknown.</p><p class="headingAnchor" id="H31"><span class="h1">FIXED DRUG ERUPTION</span><span class="headingEndMark"> — </span>Fixed drug eruption is characterized by the rapid formation of a solitary macule, plaque, or bulla after drug exposure in a sensitized individual, although multiple or diffuse lesions can be observed. The cytotoxic drugs most commonly associated with a fixed drug eruption are listed in the table  (<a class="graphic graphic_table graphicRef54060" href="/d/graphic/54060.html" rel="external">table 5</a>).</p><p>The characteristic early lesion is a sharply demarcated, erythematous, round to oval macule that develops from 30 minutes to 8 hours after drug exposure and arises in the same location after each exposure  (<a class="graphic graphic_picture graphicRef52192 graphicRef86671" href="/d/graphic/52192.html" rel="external">picture 10A-B</a>). One-half occur on the oral or genital mucosa  (<a class="graphic graphic_picture graphicRef65991" href="/d/graphic/65991.html" rel="external">picture 10D</a>). Within hours, the lesion becomes edematous, forming a plaque, which may evolve to bulla  (<a class="graphic graphic_picture graphicRef67733" href="/d/graphic/67733.html" rel="external">picture 10C</a>) and eventually to erosion. Lesions persist if the drug is continued, but they resolve within days to weeks after the drug is discontinued, leaving a postinflammatory hyperpigmentation.</p><p>Fixed drug eruption is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/15760.html" rel="external">"Fixed drug eruption"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">DIFFUSE ERYTHEMA AND EXFOLIATIVE DERMATITIS</span><span class="headingEndMark"> — </span>Diffuse erythema, which can resemble a morbilliform exanthem, has been described with <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>, <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>, and <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> [<a href="#rid95">95</a>]. Many of these eruptions are mild and self-limited, and they do not proceed to exfoliation. Drugs that are more likely to be associated with exfoliative dermatitis include <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, and, rarely, intravesical (but not intravenous) <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> [<a href="#rid96">96-99</a>]. At least some of these cases are thought to be immune mediated.</p><p class="headingAnchor" id="H1767730722"><span class="h1">SEVERE CUTANEOUS DRUG REACTIONS</span><span class="headingEndMark"> — </span>Many antineoplastic agents may cause life-threatening cutaneous adverse reactions, such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) [<a href="#rid100">100</a>].</p><p>Whether chemotherapy agents cause erythema multiforme, an immune-mediated reaction in most cases induced by infections and infrequently by drugs, remains uncertain. Similarities in clinical and histopathologic findings between SJS and erythema multiforme (ie, presence of targetoid lesions and keratinocyte necrosis) may have led to a misclassification of limited SJS as erythema multiforme in the few published cases [<a href="#rid101">101</a>]. (See  <a class="medical medical_review" href="/d/html/5559.html" rel="external">"Erythema multiforme: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H1556434661"><span class="h2">Stevens-Johnson syndrome/toxic epidermal necrolysis</span><span class="headingEndMark"> — </span>Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a serious and potentially fatal mucocutaneous drug reaction characterized by extensive necrosis and detachment of the epidermis due to massive keratinocyte apoptosis. Its severity is related to the percentage of body surface area involved, ranging from less than 10 percent in SJS to greater than 30 percent in TEN. (See  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p>Several anticancer agents have been associated with SJS/TEN  (<a class="graphic graphic_table graphicRef115844" href="/d/graphic/115844.html" rel="external">table 6</a>) [<a href="#rid100">100</a>]. Determining the drug causality in patients with cancer may be difficult due to the frequent use of multiple chemotherapy agents in combination and the concurrent use of other drugs to treat underlying conditions and comorbidities. In addition, patients with cancer may have an increased risk of SJS/TEN due to the malignancy itself [<a href="#rid102">102</a>].</p><p>SJS/TEN begins with a prodrome of fever and influenza-like symptoms followed in one to three days by an eruption of ill-defined, coalescing, erythematous macules with atypical target lesions  (<a class="graphic graphic_picture graphicRef67632" href="/d/graphic/67632.html" rel="external">picture 11</a>). As the disease progresses, vesicles and bullae form, and within days, the skin begins to slough  (<a class="graphic graphic_picture graphicRef59418" href="/d/graphic/59418.html" rel="external">picture 12C</a>). Mucosal involvement occurs in over 90 percent of cases.</p><p>Acute complications may include massive loss of fluids and electrolyte imbalance, hypovolemic shock, sepsis, and multiple organ dysfunction.</p><p>Most patients with SJS/TEN require inpatient management, often in a burn unit, because of extensive skin detachment and subsequent risk for hyponatremic dehydration and sepsis. Immediate and permanent discontinuation of the putative offending agent is warranted. Patients who develop SJS/TEN should never be re-exposed to the causative drug because of the risk of a fatal recurrence. (See  <a class="medical medical_review" href="/d/html/2092.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae"</a>.)</p><p class="headingAnchor" id="H234740659"><span class="h2">Drug reaction with eosinophilia and systemic symptoms</span><span class="headingEndMark"> — </span>Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare and potentially life-threatening, drug-induced hypersensitivity reaction that presents with a skin eruption, hematologic abnormalities (eosinophilia, atypical lymphocytosis), lymphadenopathy, and/or internal organ involvement (liver, kidney, lung). A few antineoplastic agents have been associated with DRESS, including <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a> [<a href="#rid103">103</a>] and <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> [<a href="#rid104">104</a>].</p><p>In most patients, the reaction begins two to six weeks after the initiation of the offending medication. The eruption starts as a morbilliform eruption that progresses more or less rapidly to a diffuse, confluent, and infiltrated erythema  (<a class="graphic graphic_picture graphicRef86859 graphicRef86860" href="/d/graphic/86859.html" rel="external">picture 12A-B</a>). Liver involvement occurs in 60 to 80 percent of patients. Identification and prompt withdrawal of the offending drug is the mainstay of treatment for patients with DRESS. (See  <a class="medical medical_review" href="/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p class="headingAnchor" id="H1346135749"><span class="h2">Acute generalized exanthematous pustulosis</span><span class="headingEndMark"> — </span>Acute generalized exanthematous pustulosis (AGEP) is a rare, acute eruption characterized by nonfollicular, sterile pustules on a background of erythema. It is often accompanied by fever and leukocytosis. AGEP can occur within hours and most commonly occurs within two to three days of starting a medication [<a href="#rid105">105</a>]. Although antimicrobials are the most common culprit, a few chemotherapy agents have been implicated, including <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> and taxanes [<a href="#rid106">106,107</a>]. Medications given as premedications for chemotherapy, such as histamine 2 (H2) blockers and <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, have also been linked with AGEP [<a href="#rid108">108,109</a>]. (See  <a class="medical medical_review" href="/d/html/15761.html" rel="external">"Acute generalized exanthematous pustulosis (AGEP)"</a>.)</p><p class="headingAnchor" id="H1637373605"><span class="h1">SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS AND SCLERODERMA-LIKE CHANGES</span><span class="headingEndMark"> — </span>Subacute cutaneous lupus erythematosus, which presents with annular or polycyclic, photodistributed, erythematous, and scaling lesions  (<a class="graphic graphic_picture graphicRef55903 graphicRef66580" href="/d/graphic/55903.html" rel="external">picture 13A-B</a>), has been reported following taxanes [<a href="#rid110">110-112</a>], fluoropyrimidines [<a href="#rid113">113</a>], <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> plus <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> [<a href="#rid114">114</a>], and <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> [<a href="#rid115">115</a>]. While phototoxicity may play a role in initiating or sustaining active subacute cutaneous lupus erythematosus, the pathogenesis also involves autoimmunity. This is supported by the presence of deposits of immunoglobulin G (IgG) and complement components at the dermal-epidermal junction, immunohistopathologic findings that are identical to those found in idiopathic disease. Another shared feature of drug-induced and idiopathic subacute cutaneous lupus erythematosus is the presence of circulating anti-Ro/SSA antibodies in a majority of cases. (See  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Subacute cutaneous lupus erythematosus'</a>.)</p><p>Scleroderma-like changes, consisting of edema, tightening, and induration of the skin on the trunk and extremities, have been reported in patients treated with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> [<a href="#rid116">116</a>], <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> [<a href="#rid117">117</a>], and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> [<a href="#rid118">118,119</a>]. The presentation of sclerotic changes is a relative contraindication to continued therapy. Data from the World Health Organization (WHO) pharmacovigilance database (VigiBase) found that anticancer drugs were the most represented drug class responsible for the reported cases of drug-induced systemic sclerosis [<a href="#rid120">120</a>]. These included taxane-based agents, bleomycin, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>, and <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a>. (See  <a class="medical medical_review" href="/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a>.)</p><p class="headingAnchor" id="H34"><span class="h1">MISCELLANEOUS REACTIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leg ulcers</strong> – Treatment-induced leg ulcers occasionally occur in patients taking long-term <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> for myeloproliferative disorders [<a href="#rid121">121-124</a>]. Lesions are most commonly located near the malleoli and are characteristically painful. The primary mechanism of ulcer formation may involve hydroxyurea-induced inhibition of the synthesis (S) phase of the cell cycle, leading to basal keratinocyte damage and the suppression of collagen synthesis. Discontinuation of therapy is necessary for healing; ulcers recur if treatment is reinitiated [<a href="#rid124">124</a>].</p><p></p><p class="bulletIndent1">Whether leg ulcers are more frequent in patients receiving <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> for sickle cell disease is unclear. Issues related to use of hydroxyurea in this setting are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pseudocellulitis</strong> – Pseudocellulitis has been first and most commonly reported following administration of <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> but has also been described with <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> [<a href="#rid125">125-127</a>]. Typically occurring within two to three days of chemotherapy administration, patients present with bright red erythema and pain but usually in a bilateral distribution. The pathogenesis is hypothesized to occur via accumulation of chemotherapy within the interstitial space of edematous extremities, resulting in a toxic effect. The resolution time depends on the causative drug's pharmacokinetics and may persist until the drug is displaced from the tissue [<a href="#rid128">128</a>]. Symptomatic management consists of topical steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and antihistamines.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Grover's disease</strong> – Grover's disease, or transient acantholytic dermatosis, has been reported with cytotoxic chemotherapy administration [<a href="#rid129">129</a>]. Clinically and histologically, the findings are indistinguishable from nonchemotherapy-associated presentations, though patients may be less symptomatic. Treatment is with topical steroids, with lotions or creams preferred over ointments given their less occlusive quality. (See  <a class="medical medical_review" href="/d/html/5566.html" rel="external">"Grover's disease (transient and persistent acantholytic dermatosis)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other reactions</strong> – There are many other rare cutaneous reactions that have been attributed to chemotherapy agents, including Sjögren's disease, dermatomyositis, Raynaud phenomenon, reactivation of varicella-zoster infection, porphyria, and a blistering disorder characterized as a paraneoplastic pemphigus-like phenomenon with <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a> [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/15305.html" rel="external">"Paraneoplastic pemphigus"</a>.)</p><p></p><p class="bulletIndent1">A partial list of such reactions and the associated chemotherapeutic agents can be found in the following table  (<a class="graphic graphic_table graphicRef51026" href="/d/graphic/51026.html" rel="external">table 7</a>).</p><p></p><p class="headingAnchor" id="H25381708"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxic erythema of chemotherapy</strong> – The term "toxic erythema of chemotherapy" refers to a group of cutaneous reactions induced by conventional chemotherapy agents (most frequently <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a>, fluoropyrimidines [<a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>], <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>) with overlapping clinical and histopathologic features. The most frequently seen clinical presentation involves the hands and feet and is known as "hand-foot syndrome." (See  <a class="medical medical_review" href="/d/html/142102.html" rel="external">"Toxic erythema of chemotherapy (hand-foot syndrome)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutrophilic eccrine hidradenitis</strong> – Neutrophilic eccrine hidradenitis (NEH) presents with erythematous, edematous plaques  (<a class="graphic graphic_picture graphicRef99020 graphicRef99027" href="/d/graphic/99020.html" rel="external">picture 2A-B</a>) in patients with malignancy (with or without chemotherapy), with infections, or receiving a variety of chemotherapeutic agents  (<a class="graphic graphic_table graphicRef50193" href="/d/graphic/50193.html" rel="external">table 1</a>). (See <a class="local">'Neutrophilic eccrine hidradenitis'</a> above and  <a class="medical medical_review" href="/d/html/5571.html" rel="external">"Neutrophilic dermatoses", section on 'Palmoplantar eccrine hidradenitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Photosensitivity reactions</strong> – Phototoxic and photoallergic reactions have been associated with a variety of chemotherapy agents, of which the most common is <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>. A phototoxic reaction is a nonimmunologically mediated reaction that resembles an exaggerated sunburn, with erythema, edema, pain, and tenderness in sun-exposed areas  (<a class="graphic graphic_picture graphicRef86479 graphicRef90426" href="/d/graphic/86479.html" rel="external">picture 4A-B</a>). Photoallergic reactions are a delayed hypersensitivity reaction characterized by a pruritic, papulovesicular eruption that involves sun-exposed areas but may spread to non-sun-exposed areas. Photorecall and photoenhancement reactions have been reported with methotrexate and taxanes. (See <a class="local">'Photosensitivity reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation recall dermatitis and radiation enhancement</strong> – Radiation recall dermatitis (RRD) is an inflammatory skin reaction that develops in an area of previously irradiated skin after administration of several chemotherapy agents  (<a class="graphic graphic_table graphicRef77210" href="/d/graphic/77210.html" rel="external">table 2</a>). Some drugs may enhance the efficacy and dermatologic toxicity of radiation therapy when administered concurrently or within one week of radiation therapy. They are referred to as radiation sensitizers. This synergistic interaction may be exploited clinically in situations where chemotherapy and radiation therapy are administered together to enhance the therapeutic effect. (See <a class="local">'Radiation recall dermatitis and radiation enhancement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pigmentary changes </strong>– Pigmentary changes involving the skin, nails, and mucous membranes are common in patients receiving cytotoxic drugs, particularly alkylating agents and antitumor antibiotics  (<a class="graphic graphic_table graphicRef60304" href="/d/graphic/60304.html" rel="external">table 3</a>). The hyperpigmentation can be localized or diffuse, sometimes with distinctive patterns, such as serpentine or flagellate  (<a class="graphic graphic_picture graphicRef112661" href="/d/graphic/112661.html" rel="external">picture 5</a>). Hair color changes can occur with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>. (See <a class="local">'Pigmentary changes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nail toxicities</strong> – Nail changes, such as hyperpigmentation and onycholysis  (<a class="graphic graphic_picture graphicRef63373" href="/d/graphic/63373.html" rel="external">picture 8</a>), sometimes associated with inflammatory involvement of the periungual tissues, may be induced by many medications, including alkylating agents, taxanes, antimetabolites, anthracyclines, and antitumor antibiotics  (<a class="graphic graphic_table graphicRef72242" href="/d/graphic/72242.html" rel="external">table 4</a>). (See <a class="local">'Nail toxicities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exanthematous eruptions and fixed drug eruptions</strong> – Exanthematous (maculopapular)<strong> </strong>eruptions, including morbilliform rashes  (<a class="graphic graphic_picture graphicRef54205 graphicRef70062" href="/d/graphic/54205.html" rel="external">picture 9A-B</a>), and fixed drug eruptions  (<a class="graphic graphic_picture graphicRef86671 graphicRef67733 graphicRef52192 graphicRef65991" href="/d/graphic/86671.html" rel="external">picture 10A-D</a>) may occur in association with many chemotherapeutic agents  (<a class="graphic graphic_table graphicRef54060" href="/d/graphic/54060.html" rel="external">table 5</a>). (See <a class="local">'Exanthematous (maculopapular) eruptions'</a> above and <a class="local">'Fixed drug eruption'</a> above and  <a class="medical medical_review" href="/d/html/15762.html" rel="external">"Exanthematous (maculopapular) drug eruption"</a> and  <a class="medical medical_review" href="/d/html/15760.html" rel="external">"Fixed drug eruption"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe cutaneous drug eruptions</strong> – A number of antineoplastic agents  (<a class="graphic graphic_table graphicRef115844" href="/d/graphic/115844.html" rel="external">table 6</a>) may cause severe cutaneous reactions, such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS)  (<a class="graphic graphic_picture graphicRef59418 graphicRef68458 graphicRef86859 graphicRef86860" href="/d/graphic/59418.html" rel="external">picture 12A-D</a>). SJS/TEN is a rare, life-threatening cutaneous reaction characterized by extensive necrosis and detachment of the epidermis due to massive keratinocyte apoptosis  (<a class="graphic graphic_picture graphicRef59418" href="/d/graphic/59418.html" rel="external">picture 12C</a>). Patients who develop SJS/TEN or DRESS should never be re-exposed to the causative drug because of the risk of a fatal recurrence. (See <a class="local">'Severe cutaneous drug reactions'</a> above and  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subacute cutaneous lupus erythematosus and scleroderma</strong> – Subacute cutaneous lupus erythematosus, manifested by annular or polycyclic, photodistributed, erythematous, and scaling lesions  (<a class="graphic graphic_picture graphicRef55903 graphicRef66580" href="/d/graphic/55903.html" rel="external">picture 13A-B</a>), has been reported in a few cases following <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, or <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>. Scleroderma-like changes, consisting of edema, tightening, and induration of the skin on the trunk and extremities, have been reported in patients treated with taxane-based agents, <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>, and <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a>. (See <a class="local">'Subacute cutaneous lupus erythematosus and scleroderma-like changes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uncommon reactions</strong> – Uncommon reactions, including leg ulcers, pseudocellulitis, Sjögren's disease, dermatomyositis, Raynaud phenomenon, reactivation of varicella-zoster infection, porphyria, and a paraneoplastic pemphigus-like phenomenon, have been associated with several chemotherapeutic agents  (<a class="graphic graphic_table graphicRef51026" href="/d/graphic/51026.html" rel="external">table 7</a>). (See <a class="local">'Miscellaneous reactions'</a> above.)</p><p></p><p class="headingAnchor" id="H3606055953"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Aimee S Payne, MD, PhD, and Diane MF Savarese, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40:367.</a></li><li><a class="nounderline abstract_t">Asnis LA, Gaspari AA. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol 1995; 33:393.</a></li><li><a class="nounderline abstract_t">Remlinger KA. Cutaneous reactions to chemotherapy drugs: the art of consultation. Arch Dermatol 2003; 139:77.</a></li><li><a class="nounderline abstract_t">Payne AS, James WD, Weiss RB. Dermatologic toxicity of chemotherapeutic agents. Semin Oncol 2006; 33:86.</a></li><li><a class="nounderline abstract_t">Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol 2014; 71:203.e1.</a></li><li><a class="nounderline abstract_t">Shi VJ, Levy LL, Choi JN. Cutaneous manifestations of nontargeted and targeted chemotherapies. Semin Oncol 2016; 43:419.</a></li><li><a class="nounderline abstract_t">Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008; 59:524.</a></li><li><a class="nounderline abstract_t">Nelson CA, Stephen S, Ashchyan HJ, et al. Neutrophilic dermatoses: Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease. J Am Acad Dermatol 2018; 79:987.</a></li><li><a class="nounderline abstract_t">Harrist TJ, Fine JD, Berman RS, et al. Neutrophilic eccrine hidradenitis. A distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapy. Arch Dermatol 1982; 118:263.</a></li><li><a class="nounderline abstract_t">Bailey DL, Barron D, Lucky AW. Neutrophilic eccrine hidradenitis: a case report and review of the literature. Pediatr Dermatol 1989; 6:33.</a></li><li><a class="nounderline abstract_t">Margolis DJ, Gross PR. Neutrophilic eccrine hidradenitis: a case report and review of the literature. Cutis 1991; 48:198.</a></li><li><a class="nounderline abstract_t">Brehler R, Reimann S, Bonsmann G, Metze D. Neutrophilic hidradenitis induced by chemotherapy involves eccrine and apocrine glands. Am J Dermatopathol 1997; 19:73.</a></li><li><a class="nounderline abstract_t">Flynn TC, Harrist TJ, Murphy GF, et al. Neutrophilic eccrine hidradenitis: a distinctive rash associated with cytarabine therapy and acute leukemia. J Am Acad Dermatol 1984; 11:584.</a></li><li><a class="nounderline abstract_t">Thorisdottir K, Tomecki KJ, Bergfeld WF, Andresen SW. Neutrophilic eccrine hidradenitis. J Am Acad Dermatol 1993; 28:775.</a></li><li class="breakAll">Smoller BR, Horn TD. Chemotherapy-induced drug eruptions. In: Dermatopathology in Systemic Disease, Smoller BR, Horn TD (Eds), Oxford University Press, 2001. p.298.</li><li><a class="nounderline abstract_t">Bernstein EF, Spielvogel RL, Topolsky DL. Recurrent neutrophilic eccrine hidradenitis. Br J Dermatol 1992; 127:529.</a></li><li><a class="nounderline abstract_t">Beutner KR, Packman CH, Markowitch W. Neutrophilic eccrine hidradenitis associated with Hodgkin's disease and chemotherapy. A case report. Arch Dermatol 1986; 122:809.</a></li><li><a class="nounderline abstract_t">Shear NH, Knowles SR, Shapiro L, Poldre P. Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis. J Am Acad Dermatol 1996; 35:819.</a></li><li><a class="nounderline abstract_t">Usuki A, Funasaka Y, Oka M, Ichihashi M. Tegafur-induced photosensitivity--evaluation of provocation by UVB irradiation. Int J Dermatol 1997; 36:604.</a></li><li><a class="nounderline abstract_t">Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol 2002; 14:212.</a></li><li><a class="nounderline abstract_t">DeSpain JD. Dermatologic toxicity of chemotherapy. Semin Oncol 1992; 19:501.</a></li><li><a class="nounderline abstract_t">Sibaud V. Anticancer treatments and photosensitivity. J Eur Acad Dermatol Venereol 2022; 36 Suppl 6:51.</a></li><li><a class="nounderline abstract_t">Treudler R, Georgieva J, Geilen CC, Orfanos CE. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma. J Am Acad Dermatol 2004; 50:783.</a></li><li class="breakAll">Smoller BR, Horn TD. Chemotherapy-induced drug eruptions. In: Dermatopathology in Systemic Disease, Smoller BR, Horn TD (Eds), Oxford University Press, 2001. p.298.</li><li><a class="nounderline abstract_t">Fujimoto M, Kikuchi K, Imakado S, Furue M. Photosensitive dermatitis induced by flutamide. Br J Dermatol 1996; 135:496.</a></li><li><a class="nounderline abstract_t">Leroy D, Dompmartin A, Szczurko C. Flutamide photosensitivity. Photodermatol Photoimmunol Photomed 1996; 12:216.</a></li><li><a class="nounderline abstract_t">Goldfeder KL, Levin JM, Katz KA, et al. Ultraviolet recall reaction after total body irradiation, etoposide, and methotrexate therapy. J Am Acad Dermatol 2007; 56:494.</a></li><li><a class="nounderline abstract_t">Ee HL, Yosipovitch G. Photo recall phenomenon: an adverse reaction to taxanes. Dermatology 2003; 207:196.</a></li><li><a class="nounderline abstract_t">Droitcourt C, Le Hô H, Adamski H, et al. Docetaxel-induced photo-recall phenomenon. Photodermatol Photoimmunol Photomed 2012; 28:222.</a></li><li><a class="nounderline abstract_t">DeVore KJ. Solar burn reactivation induced by methotrexate. Pharmacotherapy 2010; 30:123e.</a></li><li><a class="nounderline abstract_t">Johansson EK, Krynitz B, Holmsten M, et al. Severe Photo Toxicity Recalled by Docetaxel. Case Rep Oncol 2018; 11:751.</a></li><li><a class="nounderline abstract_t">Williams BJ, Roth DJ, Callen JP. Ultraviolet recall associated with etoposide and cyclophosphamide therapy. Clin Exp Dermatol 1993; 18:452.</a></li><li><a class="nounderline abstract_t">Andersen KE, Lindskov R. Recall of UVB-induced erythema in breast cancer patient receiving multiple drug chemotherapy. Photodermatol 1984; 1:129.</a></li><li><a class="nounderline abstract_t">Badger J, Kang S, Uzieblo A, Srinivas S. Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment. J Clin Oncol 2005; 23:7224.</a></li><li><a class="nounderline abstract_t">Markman M, Kulp B, Peterson G. Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn. Gynecol Oncol 2004; 94:578.</a></li><li><a class="nounderline abstract_t">Sollitto RB, Frank W, Palko MJ, Rogers GS. An oncology patient with an erythematous papulosquamous eruption in sun-exposed areas. Inflamed actinic keratoses due to systemic chemotherapy (fluorouracil and, possibly, interferon alfa). Arch Dermatol 1994; 130:1194, 1197.</a></li><li><a class="nounderline abstract_t">Johnson TM, Rapini RP, Duvic M. Inflammation of actinic keratoses from systemic chemotherapy. J Am Acad Dermatol 1987; 17:192.</a></li><li><a class="nounderline abstract_t">Krathen M, Treat J, James WD. Capecitabine induced inflammation of actinic keratoses. Dermatol Online J 2007; 13:13.</a></li><li><a class="nounderline abstract_t">Ilyas EN, Grana G, Green JJ. Inflammatory actinic keratoses secondary to systemic chemotherapy. Cutis 2005; 75:167.</a></li><li><a class="nounderline abstract_t">Burris HA 3rd, Hurtig J. Radiation recall with anticancer agents. Oncologist 2010; 15:1227.</a></li><li><a class="nounderline abstract_t">Kodym E, Kalinska R, Ehringfeld C, et al. Frequency of radiation recall dermatitis in adult cancer patients. Onkologie 2005; 28:18.</a></li><li><a class="nounderline abstract_t">D'ANGIO GJ, FARBER S, MADDOCK CL. Potentiation of x-ray effects by actinomycin D. Radiology 1959; 73:175.</a></li><li><a class="nounderline abstract_t">Bhangoo RS, Cheng TW, Petersen MM, et al. Radiation recall dermatitis: A review of the literature. Semin Oncol 2022; 49:152.</a></li><li><a class="nounderline abstract_t">Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001; 59:237.</a></li><li><a class="nounderline abstract_t">Schwartz BM, Khuntia D, Kennedy AW, Markman M. Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy. Gynecol Oncol 2003; 91:421.</a></li><li><a class="nounderline abstract_t">Camidge R, Price A. Radiation recall dermatitis may represent the Koebner phenomenon. J Clin Oncol 2002; 20:4130; author reply 4130.</a></li><li><a class="nounderline abstract_t">Gzell CE, Carroll SL, Suchowerska N, et al. Radiation recall dermatitis after pre-sensitization with pegylated liposomal doxorubicin. Cancer Invest 2009; 27:397.</a></li><li><a class="nounderline abstract_t">Phillips TL, Fu KK. Quantification of combined radiation therapy and chemotherapy effects on critical normal tissues. Cancer 1976; 37:1186.</a></li><li><a class="nounderline abstract_t">Shenkier T, Gelmon K. Paclitaxel and radiation-recall dermatitis. J Clin Oncol 1994; 12:439.</a></li><li><a class="nounderline abstract_t">Parry BR. Radiation recall induced by tamoxifen. Lancet 1992; 340:49.</a></li><li><a class="nounderline abstract_t">Smith KJ, Germain M, Skelton H. Histopathologic features seen with radiation recall or enhancement eruptions. J Cutan Med Surg 2002; 6:535.</a></li><li><a class="nounderline abstract_t">Yeo W, Leung SF, Johnson PJ. Radiation-recall dermatitis with docetaxel: establishment of a requisite radiation threshold. Eur J Cancer 1997; 33:698.</a></li><li><a class="nounderline abstract_t">Stelzer KJ, Griffin TW, Koh WJ. Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome. Cancer 1993; 71:1322.</a></li><li><a class="nounderline abstract_t">Burstein HJ. Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine. J Clin Oncol 2000; 18:693.</a></li><li><a class="nounderline abstract_t">Ortmann E, Hohenberg G. Treatment side effects. Case 1. Radiation recall phenomenon after administration of capecitabine. J Clin Oncol 2002; 20:3029.</a></li><li><a class="nounderline abstract_t">Castellano D, Hitt R, Cortés-Funes H, et al. Side effects of chemotherapy. Case 2. Radiation recall reaction induced by gemcitabine. J Clin Oncol 2000; 18:695.</a></li><li><a class="nounderline abstract_t">Greco FA, Brereton HD, Kent H, et al. Adriamycin and enhanced radiation reaction in normal esophagus and skin. Ann Intern Med 1976; 85:294.</a></li><li><a class="nounderline abstract_t">Greco FA, Oldham RK. Adriamycin and radiation reactions. Ann Intern Med 1977; 86:655.</a></li><li><a class="nounderline abstract_t">O'Rourke ME. Enhanced cutaneous effects in combined modality therapy. Oncol Nurs Forum 1987; 14:31.</a></li><li><a class="nounderline abstract_t">Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992; 22:613.</a></li><li><a class="nounderline abstract_t">Singal R, Tunnessen WW Jr, Wiley JM, Hood AF. Discrete pigmentation after chemotherapy. Pediatr Dermatol 1991; 8:231.</a></li><li><a class="nounderline abstract_t">Piraccini BM, Iorizzo M. Drug reactions affecting the nail unit: diagnosis and management. Dermatol Clin 2007; 25:215.</a></li><li><a class="nounderline abstract_t">Jain V, Bhandary S, Prasad GN, Shenoi SD. Serpentine supravenous streaks induced by 5-fluorouracil. J Am Acad Dermatol 2005; 53:529.</a></li><li><a class="nounderline abstract_t">Piraccini BM, Tosti A. Drug-induced nail disorders: incidence, management and prognosis. Drug Saf 1999; 21:187.</a></li><li><a class="nounderline abstract_t">Baran R, Laugier P. Melanonychia induced by topical 5-fluorouracil. Br J Dermatol 1985; 112:621.</a></li><li><a class="nounderline abstract_t">Pujol RM, Rocamora V, Lopez-Pousa A, et al. Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. J Am Acad Dermatol 1998; 39:839.</a></li><li><a class="nounderline abstract_t">Korbitz BC, Reiquam CW. Busulfan in chronic granulocytic leukemia, a spectrum of clinical considerations. Clin Med 1969; 76:16.</a></li><li><a class="nounderline abstract_t">Bandini G, Belardinelli A, Rosti G, et al. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies. Bone Marrow Transplant 1994; 13:577.</a></li><li><a class="nounderline abstract_t">Lotem M, Hubert A, Lyass O, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000; 136:1475.</a></li><li><a class="nounderline abstract_t">Issaivanan M, Mitu PS, Manisha C, Praveen K. Cutaneous manifestations of hydroxyurea therapy in childhood: case report and review. Pediatr Dermatol 2004; 21:124.</a></li><li><a class="nounderline abstract_t">Aste N, Fumo G, Contu F, et al. Nail pigmentation caused by hydroxyurea: report of 9 cases. J Am Acad Dermatol 2002; 47:146.</a></li><li><a class="nounderline abstract_t">Al-Lamki Z, Pearson P, Jaffe N. Localized cisplatin hyperpigmentation induced by pressure. A case report. Cancer 1996; 77:1578.</a></li><li><a class="nounderline abstract_t">Bronner AK, Hood AF. Cutaneous complications of chemotherapeutic agents. J Am Acad Dermatol 1983; 9:645.</a></li><li><a class="nounderline abstract_t">Hendrix JD Jr, Greer KE. Cutaneous hyperpigmentation caused by systemic drugs. Int J Dermatol 1992; 31:458.</a></li><li><a class="nounderline abstract_t">Rosman IS, Lloyd BM, Hayashi RJ, Bayliss SJ. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol 2008; 58:575.</a></li><li><a class="nounderline abstract_t">Schulte-Huermann P, Zumdick M, Ruzicka T. Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma. Dermatology 1995; 191:65.</a></li><li><a class="nounderline abstract_t">Baselga E, Drolet BA, Casper J, Esterly NB. Chemotherapy-associated supravenous hyperpigmentation. Dermatology 1996; 192:384.</a></li><li><a class="nounderline abstract_t">Todkill D, Taibjee S, Borg A, Gee BC. Flagellate erythema due to bleomycin. Br J Haematol 2008; 142:857.</a></li><li><a class="nounderline abstract_t">Mowad CM, Nguyen TV, Elenitsas R, Leyden JJ. Bleomycin-induced flagellate dermatitis: a clinical and histopathological review. Br J Dermatol 1994; 131:700.</a></li><li><a class="nounderline abstract_t">Cohen PR. Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation. World J Clin Cases 2016; 4:390.</a></li><li><a class="nounderline abstract_t">Masson Regnault M, Gadaud N, Boulinguez S, et al. Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the Literature. Dermatology 2015; 231:312.</a></li><li><a class="nounderline abstract_t">Wheeland RG, Burgdorf WH, Humphrey GB. The flag sign of chemotherapy. Cancer 1983; 51:1356.</a></li><li><a class="nounderline abstract_t">Robert C, Sibaud V, Mateus C, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol 2015; 16:e181.</a></li><li><a class="nounderline abstract_t">Sibaud V, Lebœuf NR, Roche H, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol 2016; 26:427.</a></li><li><a class="nounderline abstract_t">Chapman S, Cohen PR. Transverse leukonychia in patients receiving cancer chemotherapy. South Med J 1997; 90:395.</a></li><li><a class="nounderline abstract_t">Alimonti A, Nardoni C, Papaldo P, et al. Nail disorders in a woman treated with ixabepilone for metastatic breast cancer. Anticancer Res 2005; 25:3531.</a></li><li><a class="nounderline abstract_t">Wasner G, Hilpert F, Schattschneider J, et al. Docetaxel-induced nail changes--a neurogenic mechanism: a case report. J Neurooncol 2002; 58:167.</a></li><li><a class="nounderline abstract_t">Marks DH, Qureshi A, Friedman A. Evaluation of Prevention Interventions for Taxane-Induced Dermatologic Adverse Events: A Systematic Review. JAMA Dermatol 2018; 154:1465.</a></li><li><a class="nounderline abstract_t">Ishiguro H, Takashima S, Yoshimura K, et al. Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients. Support Care Cancer 2012; 20:2017.</a></li><li><a class="nounderline abstract_t">Thödtmann R, Sauter T, Weinknecht S, et al. A phase II trial of pemetrexed in patients with metastatic renal cancer. Invest New Drugs 2003; 21:353.</a></li><li><a class="nounderline abstract_t">Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002; 20:3533.</a></li><li><a class="nounderline abstract_t">Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589.</a></li><li><a class="nounderline abstract_t">Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21:1556.</a></li><li><a class="nounderline abstract_t">Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636.</a></li><li><a class="nounderline abstract_t">Grey MR, Flanagan NG, Kelsey PR. Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution. Clin Lab Haematol 2000; 22:111.</a></li><li><a class="nounderline abstract_t">Lee TC, Hook CC, Long HJ. Severe exfoliative dermatitis associated with hand ischemia during cisplatin therapy. Mayo Clin Proc 1994; 69:80.</a></li><li><a class="nounderline abstract_t">Bencini PL, Sala F, Crosti C, et al. Exfoliative dermatitis following intravesical therapy with mitomycin C. Int J Dermatol 1985; 24:472.</a></li><li><a class="nounderline abstract_t">Peters T, Theile-Ochel S, Chemnitz J, et al. Exfoliative dermatitis after long-term methotrexate treatment of severe psoriasis. Acta Derm Venereol 1999; 79:391.</a></li><li><a class="nounderline abstract_t">Kunkeler L, Nieboer C, Bruynzeel DP. Type III and type IV hypersensitivity reactions due to mitomycin C. Contact Dermatitis 2000; 42:74.</a></li><li><a class="nounderline abstract_t">Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs 2014; 25:225.</a></li><li><a class="nounderline abstract_t">Roujeau JC. Re-evaluation of 'drug-induced' erythema multiforme in the medical literature. Br J Dermatol 2016; 175:650.</a></li><li><a class="nounderline abstract_t">Frey N, Jossi J, Bodmer M, et al. The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. J Invest Dermatol 2017; 137:1240.</a></li><li><a class="nounderline abstract_t">Vaida I, Roszkiewicz F, Gruson B, et al. Drug rash with eosinophilia and systemic symptoms after chlorambucil treatment in chronic lymphocytic leukaemia. Pharmacology 2009; 83:148.</a></li><li><a class="nounderline abstract_t">Shaaban H, Layne T, Guron G. A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide. J Oncol Pharm Pract 2014; 20:302.</a></li><li><a class="nounderline abstract_t">Sidoroff A, Halevy S, Bavinck JN, et al. Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol 2001; 28:113.</a></li><li><a class="nounderline abstract_t">Altaykan A, Boztepe G, Erkin G, et al. Acute generalized exanthematous pustulosis induced by bleomycin and confirmed by patch testing. J Dermatolog Treat 2004; 15:231.</a></li><li><a class="nounderline abstract_t">Kim SW, Lee UH, Jang SJ, et al. Acute localized exanthematous pustulosis induced by docetaxel. J Am Acad Dermatol 2010; 63:e44.</a></li><li><a class="nounderline abstract_t">Blanes Martínez M, Silvestre Salvador JF, Vergara Aguilera G, et al. Acute generalized exanthematous pustulosis induced by ranitidine hydrochloride. Contact Dermatitis 2003; 49:47.</a></li><li><a class="nounderline abstract_t">Murase C, Takeichi T, Sugiura K, Akiyama M. Acute generalized exanthematous pustulosis triggered by acetaminophen in an IL36RN variant heterozygote. J Dermatol 2021; 48:e186.</a></li><li><a class="nounderline abstract_t">Chen M, Crowson AN, Woofter M, et al. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol 2004; 31:818.</a></li><li><a class="nounderline abstract_t">Marchetti MA, Noland MM, Dillon PM, Greer KE. Taxane associated subacute cutaneous lupus erythematosus. Dermatol Online J 2013; 19:19259.</a></li><li><a class="nounderline abstract_t">Adachi A, Horikawa T. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. J Dermatol 2007; 34:473.</a></li><li><a class="nounderline abstract_t">Weger W, Kränke B, Gerger A, et al. Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine. J Am Acad Dermatol 2008; 59:S4.</a></li><li><a class="nounderline abstract_t">Funke AA, Kulp-Shorten CL, Callen JP. Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy. Arch Dermatol 2010; 146:1113.</a></li><li><a class="nounderline abstract_t">Wiznia LE, Subtil A, Choi JN. Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent. JAMA Dermatol 2013; 149:1071.</a></li><li><a class="nounderline abstract_t">Passiu G, Cauli A, Atzeni F, et al. Bleomycin-induced scleroderma: report of a case with a chronic course rather than the typical acute/subacute self-limiting form. Clin Rheumatol 1999; 18:422.</a></li><li><a class="nounderline abstract_t">Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol 2004; 51:S73.</a></li><li><a class="nounderline abstract_t">Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol 2008; 58:545.</a></li><li><a class="nounderline abstract_t">Debien V, Petitdemange A, Bazin D, et al. New-onset systemic sclerosis and scleroderma renal crisis under docetaxel. J Scleroderma Relat Disord 2021; 6:306.</a></li><li><a class="nounderline abstract_t">Dumont A, Dolladille C, de Boysson H, et al. Drugs associated with systemic sclerosis: An updated list of suspected drugs using the WHO pharmacovigilance database. Autoimmun Rev 2022; 21:103157.</a></li><li><a class="nounderline abstract_t">Dissemond J, Körber A. Hydroxyurea-induced ulcers on the leg. CMAJ 2009; 180:1132.</a></li><li><a class="nounderline abstract_t">Sirieix ME, Debure C, Baudot N, et al. Leg ulcers and hydroxyurea: forty-one cases. Arch Dermatol 1999; 135:818.</a></li><li><a class="nounderline abstract_t">Weinlich G, Schuler G, Greil R, et al. Leg ulcers associated with long-term hydroxyurea therapy. J Am Acad Dermatol 1998; 39:372.</a></li><li><a class="nounderline abstract_t">Best PJ, Daoud MS, Pittelkow MR, Petitt RM. Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med 1998; 128:29.</a></li><li><a class="nounderline abstract_t">Korniyenko A, Lozada J, Ranade A, Sandhu G. Recurrent lower extremity pseudocellulitis. Am J Ther 2012; 19:e141.</a></li><li><a class="nounderline abstract_t">Kovacs LD, O'Donoghue M, Cogen AL. Chemotherapy-Induced Pseudocellulitis Without Prior Radiation Exposure: A Systematic Review. JAMA Dermatol 2023; 159:870.</a></li><li><a class="nounderline abstract_t">Tracey EH, Modi B, Micheletti RG. Pemetrexed-Induced Pseudocellulitis Reaction With Eosinophilic Infiltrate on Skin Biopsy. Am J Dermatopathol 2017; 39:e1.</a></li><li><a class="nounderline abstract_t">Asemota E, Reid E, Kovarik C. Gemcitabine-induced pseudocellulitis in a patient with non-small cell lung carcinoma. JAAD Case Rep 2015; 1:178.</a></li><li><a class="nounderline abstract_t">Beer J, Rosenbach M. Grover Disease Associated With Chemotherapy: Review of Potential Pathophysiology, Current Treatments, and Future Directions. J Drugs Dermatol 2020; 19:1056.</a></li></ol></div><div id="topicVersionRevision">Topic 2090 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071309" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mucocutaneous reactions to chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7544812" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cutaneous reactions to recombinant cytokine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12533171" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cutaneous reactions to chemotherapy drugs: the art of consultation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16473647" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Dermatologic toxicity of chemotherapeutic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25037800" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27178698" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cutaneous manifestations of nontargeted and targeted chemotherapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18694683" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Toxic erythema of chemotherapy: a useful clinical term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29653210" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Neutrophilic dermatoses: Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6950689" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Neutrophilic eccrine hidradenitis. A distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2649871" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Neutrophilic eccrine hidradenitis: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1834438" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Neutrophilic eccrine hidradenitis: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9056658" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Neutrophilic hidradenitis induced by chemotherapy involves eccrine and apocrine glands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6238061" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Neutrophilic eccrine hidradenitis: a distinctive rash associated with cytarabine therapy and acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8496425" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Neutrophilic eccrine hidradenitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8496425" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Neutrophilic eccrine hidradenitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1467295" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recurrent neutrophilic eccrine hidradenitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2425751" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Neutrophilic eccrine hidradenitis associated with Hodgkin's disease and chemotherapy. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8912594" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9329892" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Tegafur-induced photosensitivity--evaluation of provocation by UVB irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11880713" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cutaneous toxicities of cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1411648" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Dermatologic toxicity of chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35738806" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Anticancer treatments and photosensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15097966" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15097966" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8949460" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Photosensitive dermatitis induced by flutamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9112281" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Flutamide photosensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17187896" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ultraviolet recall reaction after total body irradiation, etoposide, and methotrexate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12920374" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Photo recall phenomenon: an adverse reaction to taxanes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23017178" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Docetaxel-induced photo-recall phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20334462" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Solar burn reactivation induced by methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30519178" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Severe Photo Toxicity Recalled by Docetaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7504596" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Ultraviolet recall associated with etoposide and cyclophosphamide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6527953" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Recall of UVB-induced erythema in breast cancer patient receiving multiple drug chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16192608" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15297208" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8085879" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : An oncology patient with an erythematous papulosquamous eruption in sun-exposed areas. Inflamed actinic keratoses due to systemic chemotherapy (fluorouracil and, possibly, interferon alfa).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3624557" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Inflammation of actinic keratoses from systemic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18319010" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Capecitabine induced inflammation of actinic keratoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15839360" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Inflammatory actinic keratoses secondary to systemic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21045191" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Radiation recall with anticancer agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15591727" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Frequency of radiation recall dermatitis in adult cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13813586" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Potentiation of x-ray effects by actinomycin D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35585004" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Radiation recall dermatitis: A review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11369064" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Characterizing the phenomenon of radiation recall dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14599876" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12351618" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Radiation recall dermatitis may represent the Koebner phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19219651" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Radiation recall dermatitis after pre-sensitization with pegylated liposomal doxorubicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/766958" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Quantification of combined radiation therapy and chemotherapy effects on critical normal tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7906725" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Paclitaxel and radiation-recall dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1351618" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Radiation recall induced by tamoxifen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12362258" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Histopathologic features seen with radiation recall or enhancement eruptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9274459" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Radiation-recall dermatitis with docetaxel: establishment of a requisite radiation threshold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7679610" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10653885" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12089233" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatment side effects. Case 1. Radiation recall phenomenon after administration of capecitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10653886" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Side effects of chemotherapy. Case 2. Radiation recall reaction induced by gemcitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/183577" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Adriamycin and enhanced radiation reaction in normal esophagus and skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/192116" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Adriamycin and radiation reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2962070" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Enhanced cutaneous effects in combined modality therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1346533" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Taxol: a novel radiation sensitizer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1745634" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Discrete pigmentation after chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17430758" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Drug reactions affecting the nail unit: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16112371" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Serpentine supravenous streaks induced by 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10487397" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Drug-induced nail disorders: incidence, management and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4005160" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Melanonychia induced by topical 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9810911" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Busulfan in chronic granulocytic leukemia, a spectrum of clinical considerations</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8054910" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11115157" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15078351" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cutaneous manifestations of hydroxyurea therapy in childhood: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12077597" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Nail pigmentation caused by hydroxyurea: report of 9 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8608546" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Localized cisplatin hyperpigmentation induced by pressure. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6643764" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Cutaneous complications of chemotherapeutic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1500233" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cutaneous hyperpigmentation caused by systemic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18249465" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589490" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8864385" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Chemotherapy-associated supravenous hyperpigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18564360" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Flagellate erythema due to bleomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7528043" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Bleomycin-induced flagellate dermatitis: a clinical and histopathological review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28035312" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26422424" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6572085" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The flag sign of chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25846098" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Nail toxicities induced by systemic anticancer treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27550571" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Dermatological adverse events with taxane chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9114829" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Transverse leukonychia in patients receiving cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16101175" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Nail disorders in a woman treated with ixabepilone for metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12164689" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Docetaxel-induced nail changes--a neurogenic mechanism: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383138" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Evaluation of Prevention Interventions for Taxane-Induced Dermatologic Adverse Events: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22086405" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14578684" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A phase II trial of pemetrexed in patients with metastatic renal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12177114" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15117980" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12697881" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860938" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792402" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8271854" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Severe exfoliative dermatitis associated with hand ischemia during cisplatin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2932403" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Exfoliative dermatitis following intravesical therapy with mitomycin C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10494723" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Exfoliative dermatitis after long-term methotrexate treatment of severe psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10703627" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Type III and type IV hypersensitivity reactions due to mitomycin C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24108082" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Life-threatening dermatologic adverse events in oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27373787" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Re-evaluation of 'drug-induced' erythema multiforme in the medical literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28202399" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19122478" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Drug rash with eosinophilia and systemic symptoms after chlorambucil treatment in chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23999760" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11168761" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15764037" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Acute generalized exanthematous pustulosis induced by bleomycin and confirmed by patch testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20633784" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Acute localized exanthematous pustulosis induced by docetaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14641127" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Acute generalized exanthematous pustulosis induced by ranitidine hydrochloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33560533" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Acute generalized exanthematous pustulosis triggered by acetaminophen in an IL36RN variant heterozygote.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15088316" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24021438" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Taxane associated subacute cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17584326" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18625380" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20956642" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23842655" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10524560" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Bleomycin-induced scleroderma: report of a case with a chronic course rather than the typical acute/subacute self-limiting form.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15280817" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Gemcitabine-associated scleroderma-like changes of the lower extremities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18342708" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Chemotherapeutic agents and the skin: An update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35387214" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : New-onset systemic sclerosis and scleroderma renal crisis under docetaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35902047" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Drugs associated with systemic sclerosis: An updated list of suspected drugs using the WHO pharmacovigilance database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19468123" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Hydroxyurea-induced ulcers on the leg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10411157" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Leg ulcers and hydroxyurea: forty-one cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9703157" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Leg ulcers associated with long-term hydroxyurea therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9424978" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Hydroxyurea-induced leg ulceration in 14 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22772033" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Recurrent lower extremity pseudocellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37379014" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Chemotherapy-Induced Pseudocellulitis Without Prior Radiation Exposure: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27415636" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Pemetrexed-Induced Pseudocellulitis Reaction With Eosinophilic Infiltrate on Skin Biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27051723" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Gemcitabine-induced pseudocellulitis in a patient with non-small cell lung carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33196735" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Grover Disease Associated With Chemotherapy: Review of Potential Pathophysiology, Current Treatments, and Future Directions.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
